

# Palbociclib in Patients With Pancreatic and Biliary Cancer With *CDKN2A* Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study

Tareq Al Baghdadi, MD<sup>1</sup>; Susan Halabi, PhD<sup>2</sup>; Elizabeth Garrett-Mayer, PhD<sup>3</sup>; Pam K. Mangat, MS<sup>3</sup>; Eugene R. Ahn, MD<sup>4</sup>; Vaibhav Sahai, MBBS, MS<sup>5</sup>; Ricardo H. Alvarez, MD, MSc<sup>6</sup>; Edward S. Kim, MD<sup>7</sup>; Kathleen J. Yost, MD<sup>8</sup>; Andrew Lawrence Rygiel, MPH<sup>3</sup>; Kaitlyn R. Antonelli<sup>3</sup>; Nicole L. Butler, MPH<sup>3</sup>; Suanna S. Bruinooge, MPH<sup>3</sup>; and Richard L. Schilsky, MD<sup>3</sup>

**PURPOSE** The Targeted Agent and Profiling Utilization Registry (TAPUR) Study identifies signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known as drug targets. In this article, data from two cohorts of patients with pancreatic and biliary cancers with *CDKN2A* loss or mutation treated with palbociclib are reported.

**METHODS** Eligible patients age 12 years and older with advanced measurable or evaluable solid tumors are provided treatment according to protocol-specified genomic matching rules. The primary study end point is objective response or stable disease of at least 16 weeks duration. For each cohort, a Simon two-stage design was used with a futility evaluation after 10 patients. Secondary end points include safety, progression-free survival (PFS), and overall survival (OS).

**RESULTS** Between July 2016 and November 2017, 12 and 10 patients with pancreatic and biliary cancer, respectively, with *CDKN2A* loss or mutation were treated with palbociclib. Twenty evaluable patients (10 per cohort) were included in the analysis. No patients had objective response or stable disease at 16 weeks, and both cohorts were closed. Two patients, neither with response, were determined to be ineligible. All patients were evaluated for safety, PFS, and OS. A median PFS of 7.2 weeks (90% CI, 4.0 to 8.0 weeks) and median OS of 12.4 weeks (90% CI, 4.7 to 23.1 weeks) were observed in the pancreatic cohort. A median PFS of 7.3 weeks (90% CI, 3.9 to 7.9 weeks) and median OS of 11.1 weeks (90% CI, 5.1 to 14.0 weeks) were observed in the biliary cohort. No unexpected toxicities were observed.

**CONCLUSION** Palbociclib monotherapy does not have clinical activity in patients with advanced pancreatic or biliary cancers with *CDKN2A* loss or mutation. Toxicity is similar to reported experience with palbociclib in other tumor types.

JCO Precis Oncol. © 2019 by American Society of Clinical Oncology

## INTRODUCTION

Cytotoxic chemotherapy is the cornerstone of treatment of patients with advanced biliary and pancreatic adenocarcinoma. Despite recent advances, outcomes remain poor with a median overall survival (OS) of less than 12 months in stage IV biliary and pancreatic cancers,<sup>1-4</sup> and new therapies are urgently needed.

Cyclin-dependent kinase (CDK) inhibitor 2A (*CDKN2A*) encodes p16INK4a, which plays an important role in cell-cycle regulation through inhibition of CDK4/6. *CDKN2A* loss or mutation is found in a wide array of malignancies and may lead to increased CDK activity.<sup>5</sup> In a report of the mutational landscape of

advanced pancreatic cancer, 46.5% of tumors harbored alterations in *CDKN2A*.<sup>6</sup> Palbociclib is an orally available selective CDK inhibitor approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer in combination with endocrine therapy. The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a prospective, phase II, pragmatic basket trial designed to identify signals of antitumor activity of commercially available targeted agents in patients with advanced cancers that harbor genomic alterations known to be drug targets. In this analysis, data for two cohorts of patients with pancreatic and biliary cancers with *CDKN2A* loss or mutation treated with single-agent palbociclib are reported.

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on June 10, 2019 and published at [ascopubs.org/journal/po](https://ascopubs.org/journal/po) on August 14, 2019; DOI <https://doi.org/10.1200/P0.19.00124>

Clinical trials information: NCT02693535.

## CONTEXT SUMMARY

### Key Objective

Genomic profiling of advanced cancers may reveal alterations that can be targeted with currently available treatments. *CDKN2A* loss or mutation, found in many malignancies, including biliary and pancreatic cancers, may lead to increased cyclin-dependent kinase activity and increased cell proliferation. This study examined whether patients with advanced biliary and pancreatic cancer with *CDKN2A* loss or mutation would be responsive to palbociclib, an oral cyclin-dependent kinase inhibitor.

### Knowledge Generated

The results demonstrated that palbociclib monotherapy has no meaningful clinical activity in patients with *CDKN2A* mutated or deleted advanced pancreatic or biliary adenocarcinoma.

### Relevance

Off-label prescribing of palbociclib for the treatment of patients with pancreatic and biliary tract cancers with *CDKN2A* loss or mutation is not recommended. These patients should be offered participation in clinical trials of new treatment approaches.

## METHODS

### Trial Design

The rationale and study design have been reported previously in detail.<sup>7</sup> Patients with advanced cancer and no standard treatment options are eligible if they have a tumor that harbors a genomic alteration known to be a target of or to predict sensitivity to one of the available study drugs. The primary study end point is antitumor activity, defined as objective response (OR) at 8 weeks or later or stable disease (SD) at 16 weeks or later from the time of enrollment. Secondary end points include progression-free survival (PFS), OS, and toxicity. For patients with solid tumors, OR is defined as complete or partial response per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. All serious adverse events and grade 3 to 5 treatment-related adverse events are reported per National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Patients are matched to one of the study drugs according to prespecified protocol matching rules on the basis of genomic testing performed by laboratories selected by clinical sites that have certification under the Clinical Laboratory Improvement Amendments and accreditation from the College of American Pathologists. Patients may not be matched to treatments that are already approved by the US Food and Drug Administration for their cancer type. Treating physicians may choose to consult with the TAPUR Molecular Tumor Board for appropriate targeted treatment options where none or multiple treatment matches surface within the TAPUR matching rules or if the treating physician would like to propose a treatment match outside the matching rules. Study treatments are administered per the treating physician in accordance with the recommended starting dose and schedule described in the package insert of each drug. Study treatment is continued until progressive disease is documented or withdrawal because of patient preference or physician recommendation. Radiographic assessment and clinical evaluation for

response evaluation are performed at 8 and 16 weeks after initiation of treatment; then every 12 weeks while the patient remains in the study; and then at the end of study treatment, where possible. Patients are placed in multiple parallel cohorts defined by study drug, genomic alteration, and tumor type.

Each cohort has the same optimal Simon two-stage design, with a total possible cohort size of 28 patients. Within each cohort, the null hypothesis is 15% if patients have OR or SD of at least 16 weeks' duration versus the alternative of 35%. Power and a one-sided type I error rate were set at 85% and 10%, respectively. The design requires 10 patients to be enrolled in a cohort in stage I and if fewer than two patients have OR or SD of at least 16 weeks' duration, the cohort is permanently closed. If two or more patients have OR or SD at 16 weeks, the cohort expands to stage II and enrolls an additional 18 patients. If at least seven patients in the total cohort have a response of at least 16 weeks' duration, the null hypothesis is rejected, and it is concluded that a signal of activity has been identified.

### Patients

Eligible patients are required to meet both protocol- and drug-specific inclusion and exclusion criteria. Protocol-specific eligibility criteria include advanced measurable or evaluable solid tumors per RECIST version 1.1; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2; and a protocol-specified genomic target identified by a test performed in a laboratory that has Clinical Laboratory Improvement Amendments certification and College of American Pathologists accreditation. The general eligibility criteria for TAPUR permit enrollment of patients ages 12 years or older; however, to meet eligibility criteria specific to palbociclib, patients must be 18 years of age or older. All patients in this cohort have an advanced cancer that has *CDKN2A* loss or mutation or amplification of *CDK4*, *CDK6*, or *CCND1* and without any *Rb* mutations. In

addition, to match to palbociclib, patients must have a cancer type other than breast and not have received food or drugs within 7 days before the start of study treatment that are known to be *CYP3A4* inhibitors or inducers. Detailed inclusion and exclusion criteria for TAPUR have been previously reported.<sup>7</sup>

Patients treated with palbociclib received standard doses (125 mg orally daily for 21 days followed by 7 days off treatment to complete a 28-day cycle) until disease progression. Radiographic tumor evaluations were performed at 8 and 16 weeks after treatment initiation.

Eligible patients in this analysis had advanced pancreatic or biliary cancer with *CDKN2A* loss or mutation. All patients were tested for alterations using next-generation sequencing (NGS) platforms, with more than half the patients determined to have *CDKN2A* loss (Table 1). Patients in both cohorts continued treatment with palbociclib until disease progression, and no patients withdrew from the study.

### Trial Oversight

The TAPUR Study protocol was reviewed and approved by a central institutional review board and, in some cases, by the local institutional review board at participating sites. Patients provide written consent before any screening activities or data collection. The TAPUR Study was designed by ASCO staff with input from ASCO volunteer members and the participating pharmaceutical companies. The TAPUR Data and Safety Monitoring Board (DSMB) is an independent board appointed by ASCO and meets biannually to monitor the study and review the safety and efficacy findings. The DSMB reviews all cohorts after stage I enrollment is complete and recommends cohorts for either closure or expansion. For expanded cohorts, the DSMB will review all completed cohorts before release of the cohort data. In the case of the cohorts reported herein, the DSMB reviewed the safety and efficacy data and determined that both cohorts should permanently close at the end of stage I enrollment and that the findings be released.

### Study End Points

The primary end point is OR, defined as complete or partial response at or before 16 weeks, or SD at 16 weeks or later as reported per RECIST version 1.1. Secondary end points

are PFS, OS, and toxicity per Common Terminology Criteria for Adverse Events (version 4.0).

### Data Analysis

OR analyses were conducted for the 20 evaluable patients in the palbociclib cohorts, known as the efficacy population. All 22 patients were included in the safety, PFS, and OS analyses. The primary end point was summarized as proportion, and 90% CIs were computed. Kaplan-Meier curves were used to estimate the PFS and OS distributions.

**TABLE 2.** Baseline Demographic and Clinical Characteristics for Each Cohort

Characteristic	Palbociclib Targeting <i>CDKN2A</i> , No. (%)	
	Pancreatic Cancer	Biliary Cancer
No. of patients	12	10
Median age, years (range)	62 (52-70)	63 (54-81)
Sex		
Male	8 (67)	5 (50)
Female	4 (33)	5 (50)
Race		
White	10 (84)	8 (80)
Black	1 (8)	1 (10)
Other	1 (8)	1 (10)
ECOG performance status		
0	3 (25)	1 (10)
1	8 (67)	6 (60)
2	1 (8)	3 (30)
Prior treatments		
Radiation therapy	2 (17)	2 (20)
No. of systemic therapies		
1	0 (0)	2 (20)
2	6 (50)	2 (20)
3	6 (50)	6 (60)
Genomic test performed		
FoundationOne	10 (83)	9 (90)
MSK-IMPACT	2 (17)	0 (0)
MI-ONCOSEQ	0 (0)	1 (10)
Patients with additional genomic alterations reported		
0	0 (0)	1 (10)
1	11 (92)	5 (50)
2	1 (8)	4 (40)
3	0 (0)	0 (0)

Abbreviations: ECOG, Eastern Cooperative Oncology Group; MI-ONCOSEQ, Michigan Oncology Sequencing Project; MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets.

**TABLE 1.** Molecular Alterations and Testing Methods for Pancreatic and Biliary Cancer Cohorts

Target	Test Platform	Molecular Alteration	Pancreatic Cancer, No. (%)	Biliary Cancer, No. (%)
<i>CDKN2A</i>	NGS	Loss	8 (67)	5 (50)
		Mutation	3 (25)	5 (50)
		VUS	1 (8)	0 (0)

Abbreviations: NGS, next-generation sequencing; VUS, variant of unknown significance.

## RESULTS

### Patients With Pancreatic Cancer

Twelve patients with pancreatic cancer and *CDKN2A* loss or mutation treated with palbociclib were enrolled in the study across seven sites from July 25, 2016, to April 28, 2017. The median age was 62 years (range, 52 to 70 years); 67% of patients were male; and 10 patients were white, one black, and one other. Three, eight, and one patient had an ECOG PS of 0, 1, and 2, respectively (Table 2).

All patients had NGS tests performed using either FoundationOne (83%; Foundation Medicine, Cambridge, MA) or Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (17%; Memorial Sloan Kettering Cancer Center, Boston, MA). Detailed information from the test reports that identified the specific *CDKN2A* variant information is listed in Table 3. The majority of patients in the cohort (67%) were identified with a *CDKN2A* loss. The remaining patients were determined to have a *CDKN2A* mutation, with the exception of one patient identified as having a *CDKN2A* variant of unknown significance. However, this patient was not included in the efficacy analysis because the patient was determined as not evaluable for response. The most common alterations identified in addition to *CDKN2A* alterations for each patient are shown in Figure 1. Other common genomic alterations noted in this cohort were mutations in *BRAF*, *FGFR1*, *FRS2*, *KRAS*, and *TP53*, with *KRAS* mutations being the most commonly reported in 10 of 12 patients.

Two patients who were enrolled and received treatment were subsequently found to be ineligible because they had not met the eligibility requirement for a hemoglobin level of 9.0 g/dL or greater at the time of enrollment. Neither ineligible patient demonstrated OR. Of the 10 eligible patients, nine experienced progression at or before 8 weeks; the remaining patient had tumor progression at 16 weeks. All patients were included in the analysis for safety, PFS,

and OS. On the basis of these findings, the cohort was closed as a result of futility. Median PFS was 7.2 weeks (90% CI, 4.0 to 8.0 weeks) and median OS was 12.4 weeks (90% CI, 4.7 to 23.1 weeks; Fig 2A).

One of the 12 patients experienced grade 3 fatigue possibly related to palbociclib. No other grade 3 or higher adverse event or serious adverse event was observed as at least possibly related to palbociclib.

### Patients With Biliary Cancer

Ten patients with biliary cancer with *CDKN2A* loss or mutation treated with palbociclib were enrolled in the study across six sites from August 9, 2016, to November 11, 2017. The median age was 63 years (range, 54 to 81 years); 50% of patients were male; and eight patients were white, one black, and one with race not specified. One, six, and three patients had an ECOG PS of 0, 1, and 2, respectively (Table 2).

Most patients in this cohort (90%) had a FoundationOne test performed, with the exception of one patient (10%) who had the NGS test performed by the Michigan Oncology Sequencing Project laboratory.<sup>8</sup> Detailed information from the tests that identified the specific *CDKN2A* variant information is listed in Table 4. Equal numbers of patients in the cohort were identified with either *CDKN2A* loss or *CDKN2A* mutation. The most common alterations identified in addition to *CDKN2A* for each patient are shown in Figure 1. Other genomic alterations noted in this cohort included *ARID1A*, *ATM*, *BRAF*, *FGFR2*, *FH*, *KRAS*, *NRAS*, *PIK3CA*, and *VHL*.


All 10 patients experienced progression at or before 10 weeks. On the basis of these findings, the cohort was closed as a result of futility. The median PFS was 7.3 weeks (90% CI, 3.9 to 7.9 weeks), and median OS was 11.1 weeks (90% CI, 5.1 to 14.0 weeks; Fig 2B).

One of the 10 patients enrolled experienced a grade 3 serious adverse event of muscle weakness and port

**TABLE 3.** Detailed *CDKN2A* Information From Test Assay for Patients in the Pancreatic Cancer Cohort

Loss/Mutation	Specific <i>CDKN2A</i> Variant	NGS Test	No. of Patients
Loss	Loss	FoundationOne	6
	Loss <i>CDKN2A</i> exon 1 and <i>CDKN2B</i>	FoundationOne	1
	p16INK4a loss and p14ARF loss exon 1 and <i>CDKN2B</i> loss	FoundationOne	1
Mutation	p16INK4a L78fs*41 and p14ARF H93fs*41+, p16INK4a R80* and p14ARF P94L	FoundationOne	1
	p14ARF exon2 p.A121_C123del; p16INK4A exon2 p.R107_A109del	MSK-IMPACT	1
	<i>CDKN2A</i> p14ARF S127F (c.380C>T) exon2; <i>CDKN2A</i> p14ARF P101S (c.301C>T) exon2; <i>CDKN2A</i> p14ARF chr9:g.18389532_c.317-3482: C DKN2Ap14ARF inv exon2; <i>CDKN2A</i> p16INK4A chr9:g.18389532_c.138: <i>CDKN2A</i> p161N K4A inv exons 1-3	MSK-IMPACT	1
VUS	A127fs*19	FoundationOne	1

Abbreviations: MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets; NGS, next-generation sequencing; VUS, variant of unknown significance.



**FIG 1.** Genomic alterations reported in patients with pancreatic and biliary cancer treated with palbociclib that targeted *CDKN2A* loss or mutation.


infection possibly related to palbociclib. Four patients experienced grade 3 or 4 adverse events of thrombocytopenia at least possibly related to palbociclib.

**DISCUSSION**

This phase II study in patients with advanced pancreatic or biliary cancers with *CDKN2A* loss or mutation treated with single-agent palbociclib demonstrated no clinical activity.

The toxicity is similar to previous reports of monotherapy with palbociclib.

*CDKN2A* is a tumor suppressor gene frequently altered by mutations, deletions, and epigenetic silencing. Its product, p16INK4a, regulates entry into the DNA synthetic phase of the cell cycle in a retinoblastoma protein (RB)-dependent manner.<sup>9</sup> The p16INK4a level increases with aging and induces cellular senescence in response to stress.<sup>10</sup>



**FIG 2.** Overall survival (OS) and progression-free survival (PFS) in patients with (A) pancreatic and (B) biliary cancer treated with palbociclib that targeted *CDKN2A* loss or mutation.

**TABLE 4.** Detailed *CDKN2A* Information From Test Assay for Patients in the Biliary Cancer Cohort

Loss/Mutation	Specific <i>CDKN2A</i> Variant	NGS Test	No. of Patients
Loss	Loss	FoundationOne	3
	<i>CDKN2A/2B</i> homozygous loss	MI-ONCOSEQ	1
	p16INK4a A4_P11del, p16INK4a L16fs*9, loss exons 2-3	FoundationOne	1
Mutation	Splice site 151-2A>G	FoundationOne	1
	p16INK4a R58* and p14ARF P72L	FoundationOne	1
	p16INK4a A36fs*17, p16INK4a N71fs*49 and p14ARF Q85fs*50+	FoundationOne	1
	Splice site 151-1G>C	FoundationOne	1
	Truncation exon 2	FoundationOne	1

Abbreviations: MI-ONCOSEQ, Michigan Oncology Sequencing Project; NGS, next-generation sequencing.

*CDKN2A* mutations/deletions occur frequently in pancreatic adenocarcinoma.<sup>11</sup> Moreover, alterations that abrogate the RB/p16 tumor suppressor pathway are seen in virtually all pancreatic carcinomas.<sup>12</sup> *CDKN2A* mutations occur in a minority of cholangiocarcinomas and are associated with a poor prognosis.<sup>13,14</sup>

Prior studies of multiple RB-positive tumors have shown that most are sensitive to some degree to CDK4/6 inhibition.<sup>15-18</sup> Preclinical studies assessing the impact of CDK4/6 inhibition on pancreatic cancer cell lines and xenograft models showed conflicting data. For example, one study showed that palbociclib inhibited the growth of pancreatic cancer cell lines but resulted in upregulation of the expression of genes that promote invasion and metastasis.<sup>19</sup> Another showed that established pancreatic cell lines displayed a relatively weak response to palbociclib, but palbociclib had potent activity in patient-derived xenografts.<sup>20</sup>

Palbociclib is approved for the treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer in combination with an aromatase inhibitor or fulvestrant.<sup>21,22</sup> Palbociclib showed promising activity in patients with liposarcoma<sup>23</sup> and *CDKN2A*-mutated non-small-cell lung cancer.<sup>24</sup> However, palbociclib was not effective in unselected patients with squamous cell lung cancer<sup>25</sup> or urothelial cancer.<sup>26</sup> Prior studies have suggested several mechanisms of resistance to CDK4/6 inhibitors in human cancer cell lines and xenograft models, including *CDK4* amplification, *RB* loss, and cyclin E1 amplification.<sup>27-31</sup> The potential for prior exposure to systemic chemotherapy to induce resistance to palbociclib through these or other mechanisms has not been explored but might have contributed to the lack of efficacy of palbociclib in this trial. It is conceivable, therefore, that the use of palbociclib alone or in combination earlier in the treatment course could be beneficial.

The association of *CDKN2A* mutations/deletions with clinical activity of CDK4/6 inhibitors is undetermined. In patients with hormone receptor-positive, HER2-negative breast cancer, *CDKN2A* mutations do not predict activity of either palbociclib or ribociclib.<sup>32,33</sup> A report revealed that *CDKN2A* mutant cancers show only intermediate sensitivity to CDK4/6 inhibition with abemaciclib, whereas genetic events that activate D-type cyclins were associated with high sensitivity.<sup>30</sup>

The effects of combining other targeted agents with palbociclib in pancreatic adenocarcinoma cell lines have been explored. The addition of a MEK inhibitor<sup>31</sup> and a mammalian target of rapamycin inhibitor<sup>30,34</sup> was synergistic. The latter may relate to metabolic reprogramming of pancreatic cancer cells by CDK4/6 inhibition, which results in increased oxidative phosphorylation, increased consumption of glucose and glutamine, and activation of the mammalian target of rapamycin pathway.<sup>34</sup> These and other novel combinations hopefully will allow successful treatment of pancreatic adenocarcinoma and other malignancies on the basis of a sound understanding of mechanisms that underlie cancer cell resistance. The development of relevant predictive biomarkers whereby treatment decisions are based on comprehensive genomic profiling is a promising and increasingly pursued strategy. To this end, studies using comprehensive genomic assessment have identified therapeutically relevant genomic alterations in 48% of patients with advanced pancreatic adenocarcinoma<sup>6</sup> and 47% of patients with cholangiocarcinoma.<sup>14</sup> In conclusion, these results from the TAPUR Study demonstrate that single-agent palbociclib has no meaningful clinical activity in patients with *CDKN2A* mutated or deleted advanced pancreatic adenocarcinoma and cholangiocarcinoma.

## AFFILIATIONS

<sup>1</sup>Michigan Cancer Research Consortium, Ypsilanti, MI

<sup>2</sup>Duke University Medical Center, Durham, NC

<sup>3</sup>American Society of Clinical Oncology, Alexandria, VA

<sup>4</sup>Cancer Treatment Centers of America, Chicago, IL

<sup>5</sup>University of Michigan Rogel Cancer Center, Ann Arbor, MI

<sup>6</sup>Cancer Treatment Centers of America, Atlanta, GA

<sup>7</sup>Levine Cancer Institute, Atrium Health, Charlotte, NC

<sup>8</sup>Cancer Research Consortium of West Michigan, Grand Rapids, MI

**CORRESPONDING AUTHOR**

Pam K. Mangat, MS, American Society of Clinical Oncology, 2318 Mill Rd, Alexandria, VA 22314; e-mail: pam.mangat@asco.org.

**PRIOR PRESENTATION**

Presented at the 2018 American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 1-5, 2018.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Susan Halabi, Elizabeth Garrett-Mayer, Pam K. Mangat, Edward S. Kim, Suanna S. Bruinooge, Richard L. Schilsky  
**Administrative support:** Andrew Lawrence Rygiel, Kaitlyn R. Antonelli, Nicole L. Butler

**Provision of study material or patients:** Eugene R. Ahn, Vaibhav Sahai, Ricardo H. Alvarez, Kathleen J. Yost

**Collection and assembly of data:** Tareq Al Baghdadi, Pam K. Mangat, Eugene R. Ahn, Vaibhav Sahai, Ricardo H. Alvarez, Edward S. Kim, Kathleen J. Yost, Andrew Lawrence Rygiel, Kaitlyn R. Antonelli, Nicole L. Butler, Richard L. Schilsky

**Data analysis and interpretation:** Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett-Mayer, Pam K. Mangat, Vaibhav Sahai, Andrew Lawrence Rygiel, Richard L. Schilsky

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated.

Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/po/author-center](http://ascopubs.org/po/author-center).

**Tareq Al Baghdadi**

**Stock and Other Ownership Interests:** Array BioPharma, AstraZeneca, Biogen, Bristol-Myers Squibb, Merck, Portola Pharmaceuticals, Spectrum Pharmaceuticals, TRACON Pharma, Celgene, Seattle Genetics, Sunesis Pharmaceuticals

**Honoraria:** Cardinal Health, Medscape

**Consulting or Advisory Role:** Celgene, Bristol-Myers Squibb, Heron Therapeutics

**Travel, Accommodations, Expenses:** Cardinal Health, Celgene, Bristol-Myers Squibb, Heron Therapeutics

**Susan Halabi**

**Consulting or Advisory Role:** Eisai, Ferring Pharmaceuticals

**Elizabeth Garrett-Mayer**

**Stock and Other Ownership Interests:** Abbott Laboratories, AbbVie, Tactical Therapeutics, Okava Pharmaceuticals

**Consulting or Advisory Role:** Deciphera, Tyme

**Eugene R. Ahn**

**Employment:** Cancer Treatment Centers of America

**Leadership:** Cancer Treatment Centers of America

**Vaibhav Sahai**

**Consulting or Advisory Role:** Celgene, Halozyme, NewLink Genetics, Ipsen, Incyte

**Research Funding:** Celgene (Inst), Bristol-Myers Squibb (Inst), Agios (Inst), Incyte (Inst), Clovis Oncology (Inst), Debiopharm Group (Inst), FibroGen (Inst), Halozyme (Inst), MedImmune (Inst), Rafael Pharmaceuticals (Inst), Ipsen (Inst)

**Ricardo H. Alvarez**

**Employment:** Cancer Treatment Centers of America

**Leadership:** Cancer Treatment Centers of America

**Consulting or Advisory Role:** Eisai, Puma Biotechnology, R-Pharma, Pfizer

**Speakers' Bureau:** Eisai, Pfizer

**Other Relationship:** Eisai, Puma Biotechnology, Pfizer

**Edward S. Kim**

**Honoraria:** AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, Takeda Pharmaceuticals, Roche, Genentech

**Consulting or Advisory Role:** AstraZeneca, Boehringer Ingelheim, Pfizer, Merck, Takeda Pharmaceuticals, Roche, Genentech

**Research Funding:** Boehringer Ingelheim, Merck, Ignyta, Genentech, Roche

**Travel, Accommodations, Expenses:** AstraZeneca, Boehringer Ingelheim, Takeda Pharmaceuticals, Genentech, Roche, Pfizer, Merck

**Kathleen J. Yost**

**Stock and Other Ownership Interests:** Pfizer (I)

**Research Funding:** Pfizer

**Other Relationship:** Pfizer, AstraZeneca

**Richard L. Schilsky**

**Research Funding:** AstraZeneca (Inst), Bayer AG (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Roche (Inst), Eli Lilly (Inst), Merck (Inst), Pfizer (Inst), Boehringer Ingelheim (Inst), Varian (Inst)

No other potential conflicts of interest were reported.

**REFERENCES**

- Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 364:1817-1825, 2011
- Von Hoff D.D., Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 369:1691-1703, 2013
- Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med* 362:1273-1281, 2010
- Sahai V, Catalano PJ, Zalupski MM, et al: Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: A phase 2 clinical trial. *JAMA Oncol* 4:1707-1712, 2018
- Witkiewicz AK, Knudsen KE, Dicker AP, et al: The meaning of p16(ink4a) expression in tumors: Functional significance, clinical associations and future developments. *Cell Cycle* 10:2497-2503, 2011
- Aguirre AJ, Nowak JA, Camarda ND, et al: Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. *Cancer Discov* 8:1096-1111, 2018
- Mangat PK, Halabi S, Bruinooge SS, et al: Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. *JCO Precis Oncol* 10.1200/PO.18.00122

8. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through integrative high-throughput sequencing: A pilot study. *Sci Transl Med* 3:111ra121, 2011
9. Medema RH, Herrera RE, Lam F, et al: Growth suppression by p16<sup>INK4</sup> requires functional retinoblastoma protein. *Proc Natl Acad Sci U S A* 92:6289-6293, 1995
10. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and aging. *Cell* 130:223-233, 2007
11. Caldas C, Hahn SA, da Costa LT, et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 8:27-32, 1994 [Erratum: *Nat Genet* 8:410, 1994]
12. Schutte M, Hruban RH, Geradts J, et al: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. *Cancer Res* 57:3126-3130, 1997
13. Churi CR, Shroff R, Wang Y, et al: Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. *PLoS One* 9:e115383, 2014
14. Lowery MA, Ptashkin R, Jordan E, et al: Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. *Clin Cancer Res* 24:4154-4161, 2018
15. Fry DW, Harvey PJ, Keller PR, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Mol Cancer Ther* 3:1427-1438, 2004
16. Finn RS, Dering J, Conklin D, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Res* 11:R77, 2009
17. Baughn LB, Di Liberto M, Wu K, et al: A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. *Cancer Res* 66:7661-7667, 2006
18. Young RJ, Waldeck K, Martin C, et al: Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. *Pigment Cell Melanoma Res* 27:590-600, 2014
19. Liu F, Korc M: Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. *Mol Cancer Ther* 11:2138-2148, 2012
20. Witkiewicz AK, Borja NA, Franco J, et al: Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. *Oncotarget* 6:15788-15801, 2015
21. Finn RS, Martin M, Rugo HS, et al: Palbociclib and letrozole in advanced breast cancer. *N Engl J Med* 375:1925-1936, 2016
22. Cristofanilli M, Turner NC, Bondarenko I, et al: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol* 17:425-439, 2016 [Erratum: *Lancet Oncol* 17:429, 431, 434, 435, 2016]
23. Dickson MA, Schwartz GK, Keohan ML, et al: Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. *JAMA Oncol* 2:937-940, 2016
24. Gopalan PK, Pinder MC, Chiappori A, et al: A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A. *J Clin Oncol* 32, 2014 (suppl; abstr 8077)
25. Edelman MJ, Redman MW, Albain KS, et al: A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. *J Clin Oncol* 35, 2017 (suppl; abstr 9056)
26. Rose TL, Chism DD, Alva AS, et al: Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. *Br J Cancer* 119:801-807, 2018
27. Gen L, Carlson BL, Schroeder MA, et al: p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. *Neuro-oncol* 14:870-881, 2012
28. Olanich ME, Sun W, Hewitt SM, et al: CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma. *Clin Cancer Res* 21:4947-4959, 2015
29. Herrera Abreu MT, Asghar U, Elliott R, et al: PI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis. *Ann Oncol* 26, 2015 (suppl)
30. Gong X, Litchfield LM, Webster Y, et al: Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib. *Cancer Cell* 32:761-776.e6, 2017
31. Franco J, Witkiewicz AK, Knudsen ES: CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. *Oncotarget* 5:6512-6525, 2014
32. Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol* 16:25-35, 2015
33. Andre F, Stemmer SM, Campone M, et al: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy by baseline tumor markers. *Cancer Res* 77, 2017 (suppl; abstr CT045)
34. Franco J, Balaji U, Freinkman E, et al: Metabolic reprogramming of pancreatic cancer mediated by CDK4/6 inhibition elicits unique vulnerabilities. *Cell Reports* 14:979-990, 2016

